Navigation Links
UCI researchers create new strategy for highly-selective chemotherapy delivery
Date:9/24/2009

Irvine, Calif. UC Irvine researchers have created a new approach that vastly improves the targeting of chemotherapeutic drugs to specific cells and organs.

Kenneth Longmuir, associate professor of physiology & biophysics, and Richard Robertson, professor of anatomy & neurobiology, used liposomes, small spheres (less-than 100 nanometer in diameter) of naturally-occurring lipid molecules, as "packages" for the cancer chemotherapeutic agent doxorubicin, and a small peptide molecule to "address" the package to the targeted tissue.

Using this technology, the research team demonstrated that the doxorubicin was directed almost entirely to the targeted site with virtually no uptake by other organs, including lung, kidney and heart.

Their study appears online in the International Journal of Pharmaceutics.

Their approach is based on the fact that all tissues and organs, including all tumors, are surrounded by a dense region of sugar-containing molecules called polysaccharides. Most importantly, the particular chemical composition of the polysaccharides is different in each tissue and organ of the body. The chemical compositions of the polysaccharides of tumor regions are also different from normal tissue.

The research team developed a nanocarrier system that can recognize specific types of polysaccharide, and has demonstrated effective, organ-specific delivery of nanocarriers, and their therapeutic contents, based upon this polysaccharide-targeting approach.

In their study, the researchers used a peptide derived from a protein found in the microorganism Plasmodium, which is an organism well-known for its exceptional ability to exclusively target the polysaccharides of liver following entry into the bloodstream.

The drug doxorubicin is a chemotherapeutic agent commonly used as treatment for a variety of cancers. Although it is an effective anti-cancer agent, the usefulness of doxorubicin is compromised by its serious side effects on normal tissue. When administered in a chemotherapeutic regimen, doxorubicin distributes widely in the body, including the heart, rather than specifically in tumor regions.

The serious heart damage that results from systemic administration places limits on the dosage that a patient can receive. By encapsulating doxorubicin into a liposome package and including a peptide targeting message on the carrier, Longmuir, Robertson and co-workers demonstrated that doxorubicin can be effectively delivered to the liver, and away from the heart, with a specificity of greater than 100:1.

The next step in this investigation is to test the properties of the delivery system in several experimental cancer models. Liposomes with peptides are being developed that specifically address the unique features of tumors, in order to rapidly and effectively deliver chemotherapeutic agents to tumor regions.


'/>"/>

Contact: Tom Vasich
tmvasich@uci.edu
949-824-6455
University of California - Irvine
Source:Eurekalert

Related medicine news :

1. Pancreatic cancer: Researchers find drug that reverses resistance to chemotherapy
2. VA Honors Eye Researchers With Olin Teague Award
3. Researchers find drug-eluting stents safe, effective for PCI in diabetics
4. Researchers Propose Improved Cervical Cancer Screening
5. Researchers Perfect the View of Heart Disease
6. Mayo Clinic researchers lead national trial testing new treatment for chronic, severe indigestion
7. Indiana U medical researchers boost research and jobs with stimulus legislation grants
8. Canadian researchers discover the first-ever link between intelligence and curiosity
9. MUSC Researchers Concerned About Online Drug Availability
10. UCLA researchers develop biomarker for rapid relief of major depression
11. UCSB researchers develop drug delivery system using nanoparticles and lasers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
Breaking Medicine Technology: